{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:52:49Z","timestamp":1772711569628,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ijcard.2020.11.071","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T03:05:30Z","timestamp":1607396730000},"page":"138-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Sacubitril\/valsartan for the management of heart failure: A perspective viewpoint on current evidence"],"prefix":"10.1016","volume":"327","author":[{"given":"Massimo","family":"Volpe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Bay\u00e9s-Gen\u00eds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Simone","family":"Deichl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allegra","family":"Battistoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkert","family":"Pieske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2020.11.071_bb0005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(18)31737-9","article-title":"Heart failure: the need for improved treatment and care","volume":"392","author":"The Lancet","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.11.071_bb0010","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2020.11.071_bb0015","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ijcard.2020.11.071_bb0020","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","article-title":"Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF trial","volume":"139","author":"Morrow","year":"2019","journal-title":"Circulation."},{"issue":"7","key":"10.1016\/j.ijcard.2020.11.071_bb0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","article-title":"Natriuretic peptides in cardiovascular diseases: current use and perspectives","volume":"35","author":"Volpe","year":"2014","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.ijcard.2020.11.071_bb0030","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A test in context: neprilysin: function, inhibition, and biomarker","volume":"68","author":"Bayes-Genis","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"27","key":"10.1016\/j.ijcard.2020.11.071_bb0035","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.ijcard.2020.11.071_bb0040","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"6","key":"10.1016\/j.ijcard.2020.11.071_bb0045","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation."},{"issue":"11","key":"10.1016\/j.ijcard.2020.11.071_bb0050","first-page":"1342","article-title":"2017 comprehensive update of the Canadian cardiovascular society guidelines for the management of heart failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Can. J. Cardiol."},{"issue":"11","key":"10.1016\/j.ijcard.2020.11.071_bb0055","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"PROVE-HF investigators. Association of Change in N-terminal pro\u2013B-type natriuretic peptide following initiation of Sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA."},{"issue":"11","key":"10.1016\/j.ijcard.2020.11.071_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2019.12843","article-title":"EVALUATE-HF investigators. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ijcard.2020.11.071_bb0065","first-page":"933","article-title":"Association between sacubitril\/valsartan initiation and health status outcomes in heart failure with reduced ejection fraction","volume":"7","author":"Khariton","year":"2019","journal-title":"J. Am. Coll. Cardiol. HF"},{"issue":"6","key":"10.1016\/j.ijcard.2020.11.071_bb0070","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2020.11.071_bb0075","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/CIRCULATIONAHA.118.034755","article-title":"Is sacubitril\/valsartan (also) an antiarrhythmic drug?","volume":"138","author":"Sarrias","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2020.11.071_bb0080","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"6","key":"10.1016\/j.ijcard.2020.11.071_bb0085","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"PIONEER-HF investigators. Angiotensin-Neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ijcard.2020.11.071_bb0090","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"TRANSITION investigators. Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"17","key":"10.1016\/j.ijcard.2020.11.071_bb0095","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"PARAGON-HF investigators and committees. PARAGON-HF investigators and committees. Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ijcard.2020.11.071_bb0100","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation."},{"issue":"5","key":"10.1016\/j.ijcard.2020.11.071_bb0105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation."},{"issue":"3","key":"10.1016\/j.ijcard.2020.11.071_bb0110","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ehf2.12694","article-title":"Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial","volume":"7","author":"Wachter","year":"2020","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ijcard.2020.11.071_bb0115","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2020.05.084","article-title":"Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: a contemporary meta-analysis","volume":"316","author":"Gallo","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.11.071_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1766","article-title":"The neglected issue of cardiac amyloidosis in trials on heart failure with preserved ejection fraction in the elderly","author":"Russo","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"25","key":"10.1016\/j.ijcard.2020.11.071_bb0125","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/eurheartj\/ehaa184","article-title":"A putative placebo analysis of the effects of sacubitril\/valsartan in heart failure across the full range of ejection fraction","volume":"41","author":"Vaduganathan","year":"2020","journal-title":"Eur. Heart J."},{"issue":"40","key":"10.1016\/j.ijcard.2020.11.071_bb0130","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur. Heart J."},{"issue":"26","key":"10.1016\/j.ijcard.2020.11.071_bb0135","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.ijcard.2020.11.071_bb0140","first-page":"763","article-title":"Heart failure with mid-range (borderline) ejection fraction: clinical implications and future directions","volume":"5","author":"Hsu","year":"2017","journal-title":"J. Am. Coll. Cardiol. HF"},{"issue":"11","key":"10.1016\/j.ijcard.2020.11.071_bb0145","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor Neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation."},{"issue":"2","key":"10.1016\/j.ijcard.2020.11.071_bb0150","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ejhf.1673","article-title":"European Society of Cardiology\/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"21","key":"10.1016\/j.ijcard.2020.11.071_bb0155","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF committees and investigators. DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ijcard.2020.11.071_bb0160","first-page":"30254","article-title":"Effect of Dapagliflozin in patients with HFrEF treated with sacubitril\/valsartan: the DAPA-HF trial [published online ahead of print, 2020 Jul 5]","volume":"S2213\u20131779","author":"Solomon","year":"2020","journal-title":"J. Am. Coll. Cardiol. HF"},{"key":"10.1016\/j.ijcard.2020.11.071_bb0165","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022190","article-title":"For the EMPEROR-reduced trial investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ijcard.2020.11.071_bb0170","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"VICTORIA study group. Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.11.071_bb0175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ahj.2017.02.034","article-title":"PARADIGM-HF investigators and committees. The effects of sacubitril\/valsartan on coronary outcomes in PARADIGM-HF","volume":"188","author":"Mogensen","year":"2017","journal-title":"Am. Heart J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732034242X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732034242X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:50:49Z","timestamp":1759092649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752732034242X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":35,"alternative-id":["S016752732034242X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.11.071","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sacubitril\/valsartan for the management of heart failure: A perspective viewpoint on current evidence","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.11.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}